Late Breaking Abstract - Sustained FEV1 improvements with mepolizumab up to 104 weeks in patients with COPD and less severe airflow obstruction: Post hoc analysis of the MATINEE Phase III study
Bibliographic record
Abstract
Background: MATINEE assessed the efficacy of mepolizumab, a humanised monoclonal antibody specifically targeting interleukin-5, in patients with COPD up to Week (Wk) 104. Aims: Assess pre-bronchodilator FEV1 change from baseline to Wk 104. Methods: MATINEE ( NCT04133909 ) was a Phase III randomised, placebo-controlled, parallel-group trial enrolling a wide spectrum of patients with COPD, a history of exacerbations, and screening blood eosinophil count ≥300 cells/µL. Patients aged ≥40 years were randomised 1:1 to mepolizumab 100 mg or placebo, administered subcutaneously every 4 wks for a fixed 52-wk or variable 52–104-wk duration, alongside inhaled triple therapy. We report post hoc analyses of FEV1 change from baseline to Wk 104, in patients treated for 52–104 wks, and by GOLD status (FEV1 predicted: GOLD 2, 50–<80%; GOLD 3, 30–<50%; GOLD 4, <30%). Results: Of 804 randomised and treated patients, 459 (233 mepolizumab/226 placebo) participated up to 104 wks. FEV1 (mL) improved from baseline to Wk 52 with mepolizumab and placebo (LS mean [SE] change: 31.9 [22.4] vs 38.9 [22.4]; p>0.05); by Wk 104 there was stabilisation in FEV1 with mepolizumab vs a reduction with placebo (27.8 [25.9] vs −13.1 [27.4]; p>0.05). At Wk 104, improvements in FEV1 with mepolizumab versus placebo were seen for GOLD 2 (n=336: 49.8 [34.5] vs –23.0 [34.9]) and GOLD 4 (n=106: 80.9 [60.1] vs −16.7 [62.3]), but with no treatment difference for GOLD 3 (n=318: −16.0 [40.3] vs −17.6 [47.0]). Conclusions: Mepolizumab was associated with lung function stabilisation up to Wk 104, particularly in patients with GOLD stage 2 and 4. Funding: GSK (208657).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.005 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.011 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".